Atrium Therapeutics (RNA)
Targets genetic drivers of rare cardiomyopathies with tissue-directed siRNA medicines.
$8.43
vs last close−0.79 (−8.60%)
Something off on this page? Send us feedback.
13F · 13D/G · Form 4
| Institutions | 84.59% | 14.47M shares | |
|---|---|---|---|
| 159 holders · as of Jun 30, 2026 | |||
| Insiders | — | 491.7K shares | |
| 8 holders · as of Sep 22, 2026 | |||
institutions as of Jun 30, 2026 · holders as of their latest filing
No reliable share count is available for this listing, so stakes are shown as shares, not percentages.
The institutional percentage is the one reported with the filings, not one recomputed on the share count here.
13F, as of Jun 30, 2026
159 holders · 14.47M shares · 41 new positions · 89 increased · 34 reduced · 46 closed
| Holder | Shares | % outstanding | Chg q/q | Filed |
|---|---|---|---|---|
| Sessa Capital Im, L.P. | 1.50M | +948.6K | Aug 14, 2026 | |
| Price T Rowe Associates Inc /MD/ | 1.47M | −80.2K | Aug 14, 2026 | |
| BlackRock, Inc. | 1.45M | +242.2K | Aug 7, 2026 | |
| Vanguard Capital Management LLC | 730.8K | +104.0K | Aug 13, 2026 | |
| CRCM LP | 641.5K | +641.5Knew | Aug 18, 2026 | |
| Tig Advisors, LLC | 561.5K | −46.0K | Aug 14, 2026 | |
| Geode Capital Management, LLC | 386.9K | +67.1K | Aug 12, 2026 | |
| Two Sigma Investments, LP | 345.5K | +166.9K | Aug 14, 2026 |
13D/G · 5% or more, as filed
| Holder | % of class | Shares | Form | Filed |
|---|---|---|---|---|
| Avoro Capital Advisors LLCincl. Behzad Aghazadeh | 8.30% | 9.94M | 13G | Nov 14, 2024 |
| Wellington Group Holdings LLPincl. Wellington Management Group LLP, Wellington Investment Advisors Holdings LLP +1 more | 5.97% | 7.03M | 13G | Nov 8, 2024 |
Form 4
Latest trades
No open-market trades in the last 12 months.
House and Senate disclosures
Not reported.